|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Hologic, Inc. (NASDAQ:HOLX), a leading provider of diagnostic imaging systems for women’s health. |
|---|---|
| Transferring Party | The breast cushion business of BioLucent, Inc., a manufacturer radiolucent foam cushions that cover the cold, hard surfaces of mammography equipment and brachytherapy products. |
| Sector | Medical Devices |
| Date | September 20, 2007 |
| Analysis BioLucent's patented MammoPad is designed to reduce the discomfort that inhibits many women from getting regular mammography screenings. The deal strengthens Hologic's capabilities and customer relationships in the growing mammography market. Biolucent retains its brachytherapy business. Deal value -- $70m, plus earnouts not to exceed $15m based on achieving revenue targets. '06 BioLucent sales were $17m (4.1x), 42% increase over '05. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |